Skip to content

RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)

RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07744958
Enrollment
100
Registered
2026-08-04
Start date
2026-09-01
Completion date
2029-12-01
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Invasive Bladder Cancer (MIBC)

Keywords

Bladder Sparing, Muscle invasive bladder cancer, urothelial carcinoma

Brief summary

Removal of the urinary bladder (radical cystectomy) is a major surgical procedure that can have a permanent impact on a patient's quality of life. Consequently, some patients, despite having received comprehensive counseling and completing systemic therapy, decide against subsequent surgery or alternative radiotherapy. Recent scientific studies suggest that, for selected patients, an attempt at bladder preservation may be a medically justifiable option. However, it remains unclear which patients are truly suitable candidates for bladder-preserving management and which are not. The aim of this registry is therefore to collect and analyze clinical data from this specific patient population.

Interventions

OTHERNone. Registry.

None. Registry.

Sponsors

Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged \>= 18 years, capable of providing informed consent * Histologically confirmed muscle-invasive urothelial carcinoma of the urinary bladder * Received perioperative systemic therapy in accordance with current guidelines and subsequently decline cystectomy or radiotherapy

Exclusion criteria

* Age \< 18 years * Lack of capacity to provide informed consent * No histological confirmed muscle-invasive urothelial carcinoma * No prior preoperative systemic therapy

Design outcomes

Primary

MeasureTime frameDescription
2 year MFS2 YearsMetastatic free survival after two years

Contacts

CONTACTCamilla Grunewald, Dr. med.
camillamarisa.grunewald@med.uni-duesseldorf.de00492118119353

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026